How has been the historical performance of Eiko Lifescience?

Answer:The historical performance of Eiko Lifescience shows significant growth in net sales and profitability over the years, culminating in a positive trend by March 2025.

Breakdown:
Eiko Lifescience's net sales increased dramatically from 2.34 Cr in March 2018 to 37.66 Cr in March 2025, reflecting a strong upward trajectory. Total operating income followed a similar trend, rising from 2.34 Cr in March 2018 to 37.66 Cr in March 2025. The company's total expenditure also grew, but at a slower pace, from 1.99 Cr in March 2018 to 34.90 Cr in March 2025, leading to an operating profit (PBDIT) of 3.48 Cr in March 2025, a significant recovery from a loss of 4.50 Cr in March 2020. Profit before tax reached 2.92 Cr in March 2025, compared to a loss of 4.93 Cr in March 2020, and profit after tax improved to 2.18 Cr from a loss of 3.62 Cr in March 2020. The consolidated net profit for March 2025 was 2.11 Cr, a notable turnaround from a loss of 1.91 Cr in March 2020. The company's total assets grew from 10.95 Cr in March 2018 to 66.10 Cr in March 2025, while total liabilities increased from 10.95 Cr to 66.10 Cr in the same period. Cash flow from operating activities was positive at 2.00 Cr in March 2025, contributing to a closing cash balance of 11.00 Cr. Overall, Eiko Lifescience has shown a robust recovery and growth in its financial performance over the years.